Evercore ISI upgraded Zimmer Biomet (ZBH) to Outperform from In Line with a price target of $120, up from $94.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 28
- Zimmer Biomet: Solid Long-Term Setup but Execution Risks and Conservative Guidance Justify Hold Rating
- JPMorgan sees 2026 as ‘pivotal year’ for Zimmer Biomet
- Roku upgraded, Lockheed downgraded: Wall Street’s top analyst calls
- Zimmer Biomet, OneStep announce exclusive collaboration agreement